Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Antiviral Res. 2019 Jul 24;170:104567. doi: 10.1016/j.antiviral.2019.104567

Figure 1: Polyphenylene carboxymethylene (PPCM) interferes with EBOV replication.

Figure 1:

EBOV replication in (A-C) Vero, (D-F) HeLa, and (G-I) VK2/E6E7 cells at day 5 post-infection. Assay performed using a high and low multiplicity of infection (MOI) with PPCM treatments starting either 1h post-infection (no pre-treatment) or 1h prior infection (pre-treatment). The horizontal dotted line corresponds to the detection limit. Automated counting of infected (C) Vero, (F) HeLa, or (I) VK2/E6E7 cells per field of view under 10x magnification using CellProfiler. Results are expressed as the average of 3 repetitions; error bars represent standard deviations.

*, P < 0.05 **, P < 0.01; ***, P < 0.001 (ANOVA-Tukey’s multiple-comparison test).